Assessing Metabolic Risk Factors for LVSI in Endometrial Cancer: A Cross-Sectional Study

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA. 2022;72(1):7–33. doi:10.3322/caac.21708
   Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA. 2016;66(2):115–132. doi:10.3322/caac.21338
   Web of Science ®Google Scholar
• Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12. doi:10.21147/j.issn.1000-9604.2018.01.01
   PubMed Web of Science ®Google Scholar
• Mili N, Paschou SA, Goulis DG, et al. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74(3):478–497. doi:10.1007/s12020-021-02884-x
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45(1):28–36. doi:10.1007/s12020-013-9973-3
   PubMed Web of Science ®Google Scholar
• Kitson SJ, Lindsay J, Sivalingam VN, et al. The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: a prospective case control study. Gynecol Oncol. 2018;148(1):154–160. doi:10.1016/j.ygyno.2017.11.019
   PubMed Web of Science ®Google Scholar
• Chinese Medical Association. The Suggestion on Chinese Metabolic Syndrome. Shanghai, China: Chinese Medical Association; 2004.
   Google Scholar
• Guo J, Ye F, Jiang X, et al. Drp1 mediates high glucose-induced mitochondrial dysfunction and epithelial-mesenchymal transition in endometrial cancer cells. Exp Cell Res. 2020;389(1):111880. doi:10.1016/j.yexcr.2020.111880
   PubMed Web of Science ®Google Scholar
• Gu CJ, Xie F, Zhang B, et al. High glucose promotes epithelial-mesenchymal transition of uterus endometrial cancer cells by increasing ER/GLUT4-mediated VEGF secretion. Cell Physiol Biochem. 2018;50(2):706–720. doi:10.1159/000494237
   PubMedGoogle Scholar
• Wang G, Liu X, Wang D, et al. Identification and development of subtypes with poor prognosis in pan-gynecological cancer based on gene expression in the glycolysis-cholesterol synthesis axis. Front Oncol. 2021;11:636565. doi:10.3389/fonc.2021.636565
   PubMed Web of Science ®Google Scholar
• Tortorella L, Restaino S, Zannoni GF, et al. Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. J Gynecol Oncol. 2021;32(2):e11. doi:10.3802/jgo.2021.32.e11
   PubMed Web of Science ®Google Scholar
• Restaino S, Tortorella L, Dinoi G, et al. Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: prognostic and clinical implications. Eur J Cancer. 2021;142:29–37. doi:10.1016/j.ejca.2020.10.011
   PubMed Web of Science ®Google Scholar
• Kim SI, Yoon JH, Lee SJ, et al. Prediction of lymphovascular space invasion in patients with endometrial cancer. Int J Med Sci. 2021;18(13):2828–2834. doi:10.7150/ijms.60718
   PubMed Web of Science ®Google Scholar
• Stålberg K, Bjurberg M, Borgfeldt C, et al. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - A Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncol. 2019;58(11):1628–1633. doi:10.1080/0284186X.2019.1643036
   PubMed Web of Science ®Google Scholar
• Bosse T, Peters EE, Creutzberg CL, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer–A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51(13):1742–1750. doi:10.1016/j.ejca.2015.05.015
   PubMed Web of Science ®Google Scholar
• Kokts-Porietis RL, McNeil J, Nelson G, et al. Prospective cohort study of metabolic syndrome and endometrial cancer survival. Gynecol Oncol. 2020;158(3):727–733. doi:10.1016/j.ygyno.2020.06.488
   PubMed Web of Science ®Google Scholar
• Tong Y, Xie X, Mao X, et al. Low red blood cell count as an early indicator for myometrial invasion in women with endometrioid endometrial carcinoma with metabolic syndrome. Cancer Manag Res. 2020;12:10849–10859. doi:10.2147/CMAR.S271078
   PubMed Web of Science ®Google Scholar
• Yang X, Li X, Dong Y, et al. Effects of metabolic syndrome and its components on the prognosis of endometrial cancer. Front Endocrinol. 2021;12:780769. doi:10.3389/fendo.2021.780769
   PubMed Web of Science ®Google Scholar
• Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet. 2009;105(2):109. doi:10.1016/j.ijgo.2009.02.010
   PubMed Web of Science ®Google Scholar
• Rutgers JK. Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma. Future Oncol. 2015;11(23):3207–3218. doi:10.2217/fon.15.262
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17. doi:10.1016/0090-8258(83)90111-7
   PubMed Web of Science ®Google Scholar
• Giannone G, Attademo L, Scotto G, et al. Endometrial cancer stem cells: role, characterization and therapeutic implications. Cancers. 2019;11(11):1820. doi:10.3390/cancers11111820
   PubMed Web of Science ®Google Scholar
• Perrone E, De Felice F, Capasso I, et al. The immunohistochemical molecular risk classification in endometrial cancer: a pragmatic and high-reproducibility method. Gynecol Oncol. 2022;165(3):585–593. doi:10.1016/j.ygyno.2022.03.009
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Z, Yu X, et al. The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol. 2010;117(1):41–46. doi:10.1016/j.ygyno.2009.12.029
   PubMed Web of Science ®Google Scholar
• Guo H, Kong W, Zhang L, et al. Reversal of obesity-driven aggressiveness of endometrial cancer by metformin. Am J Cancer Res. 2019;9(10):2170–2193.
   PubMed Web of Science ®Google Scholar
• Yang X, Cheng Y, Zhou J, et al. Targeting cancer metabolism plasticity with JX06 nanoparticles via inhibiting PDK1 combined with metformin for endometrial cancer patients with diabetes. Adv Sci. 2022;9(8):e2104472. doi:10.1002/advs.202104472
   Web of Science ®Google Scholar
• Simon MS, Hastert TA, Barac A, et al. Cardiometabolic risk factors and survival after cancer in the Women’s Health Initiative. Cancer. 2021;127(4):598–608. doi:10.1002/cncr.33295
   PubMed Web of Science ®Google Scholar
• Panyavaranant P, Manchana T. Preoperative markers for the prediction of high-risk features in endometrial cancer. World J Clin Oncol. 2020;11(6):378–388. doi:10.5306/wjco.v11.i6.378
   PubMed Web of Science ®Google Scholar
• Majid S, Rydén L, Manjer J. Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients. World J Surg Oncol. 2018;16(1):54. doi:10.1186/s12957-018-1353-2
   PubMed Web of Science ®Google Scholar
• Jaishankar S, Pifer PM, Bhargava R, et al. Is substantial lymphovascular space invasion prognostic for clinical outcomes in type ii endometrial cancer? Clin Oncol. 2022;34(7):452–458. doi:10.1016/j.clon.2022.02.018
   Web of Science ®Google Scholar
• Dai Y, Dong Y, Cheng Y, et al. Prognostic significance of lymphovascular space invasion in patients with endometrioid endometrial cancer: a retrospective study from a single center. J Gynecol Oncol. 2020;31(3):e27. doi:10.3802/jgo.2020.31.e27
   PubMed Web of Science ®Google Scholar
• Sollberger TL, Gavrilyuk O, Rylander C. Excess body weight and incidence of type 1 and type 2 endometrial cancer: the Norwegian women and cancer study. Clin Epidemiol. 2020;12:815–824. doi:10.2147/CLEP.S253866
   PubMed Web of Science ®Google Scholar
• Marín-Aguilera M, Pereira MV, Jiménez N, et al. Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes. Cancers. 2021;13(19):4960. doi:10.3390/cancers13194960
   PubMed Web of Science ®Google Scholar
• Baek AE, Yu YA, He S, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017;8(1):864. doi:10.1038/s41467-017-00910-z
   PubMed Web of Science ®Google Scholar
• Chen Y, Lee K, Liang Y, et al. A cholesterol homeostasis-related gene signature predicts prognosis of endometrial cancer and correlates with immune infiltration. Front Genet. 2021;12:763537. doi:10.3389/fgene.2021.763537
   PubMed Web of Science ®Google Scholar
• Kho PF, Amant F, Annibali D, et al. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. Int J Cancer. 2021;148(2):307–319. doi:10.1002/ijc.33206
   PubMed Web of Science ®Google Scholar
• Feinberg J, Albright B, Black J, et al. Ten-year comparison study of type 1 and 2 endometrial cancers: risk factors and outcomes. Gynecol Obstet Invest. 2019;84(3):290–297. doi:10.1159/000493132
   PubMed Web of Science ®Google Scholar
• Barnes BO, Regan JF, Nelson WO. Improvement in experimental diabetes following the administration of amniotin. JAMA. 1933;101(12):926–927. doi:10.1001/jama.1933.02740370030008
   Google Scholar
• Gregorio KCR, Laurindo CP, Machado UF. Estrogen and glycemic homeostasis: the fundamental role of nuclear estrogen receptors ESR1/ESR2 in glucose transporter GLUT4 regulation. Cells. 2021;10(1):99. doi:10.3390/cells10010099
   PubMed Web of Science ®Google Scholar
• Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39. doi:10.1136/ijgc-2020-002230
   PubMed Web of Science ®Google Scholar
• Antonio R, Antonio T, Diego R, et al. Lymphovascular space invasion in endometrial carcinoma: a prognostic factor independent from molecular signature. Gynecol Oncol. 2022;165(1):192–197. doi:10.1016/j.ygyno.2022.01.013
   PubMed Web of Science ®Google Scholar
• Karnezis AN, Leung S, Magrill J, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017;3(4):279–293. doi:10.1002/cjp2.82
   PubMedGoogle Scholar
• Bayramoglu D, Seçilmiş Kerimoğlu Ö, Bayramoğlu Z, et al. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods. Ginekol Pol. 2022. doi:10.5603/GP.a2021.0177
   PubMed Web of Science ®Google Scholar